Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer—the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago.
Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.
This Kalorama Information report - Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis - focuses on both preventive and therapeutic cancer vaccines in development. The following cancers for which there are vaccines in development or where there is a potential are profiled:
The report also includes current issues and trends affecting the industry.
This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.
Issues and trends discussed in The Emerging Cancer Vaccine Market include:
For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.
All market data pertains to the world market at the manufacturers’ level. The years outlined in this study include projected markets for 2010 thru 2015. Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each vaccine segment covered. Competitive analysis is provided for the year 2015 for the developing and emerging market. The projected competitive analysis for 2015 was based on products in late stage development, probability of approval and marketing, and demographic trends.
Several companies have promising research and development activities for cancer vaccines. Additionally, many companies are in early stage development with a focused effort on providing favorable results in treating cancer. Many of these companies are:
The approval of Dendreon’s prostate cancer vaccine Provenge in April was a boon for a nascent cancer vaccine industry that had suffered several setbacks, and should lead to an influx of market opportunities and a surge in regulatory activity, according to Kalorama Information. In its newly published report, Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition, the healthcare market research publisher notes that it believes a $7.7 billion market for cancer vaccines is a realistic estimate for 2015.
Kalorama believes the approval of Provenge by the FDA will likely reinstall investor confidence in cancer vaccines, which had been damaged by poor commercial results in previous therapeutic vaccine approvals and disappointing Phase III studies in other once promising products such as CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope.
“This was a speculative market a decade ago, and one with its share of failed attempts,” said Melissa Elder, analyst for Kalorama Information. “Provenge’s approval and the cervical cancer vaccines represent real achievements for the therapeutic treatment of cancers using vaccines.”
Kalorama indicates that the response to Provenge has shown the market could become highly competitive within just a few years. The areas expected to display the highest competition, according to Kalorama’s research, include melanoma, lymphoma, cervical, renal and prostate cancer. These areas have a wide range of research and development activities brewing from preclinical trials to Phase III. Many of the products already in Phase III development have orphan drug status, SPA status, or Fast Track status. This provides a promising future for many of these products.
More information is available from Kalorama Information’s report, Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis, 4th Edition, which focuses on preventive and therapeutic cancer vaccines in development for a variety of cancers including cervical, colon/rectal, lung, lymphoma, melanoma, prostate, breast, gastrointestinal, renal, brain, bladder, ovarian and leukemia. The report details market forecasts through 2015, products in development, trends and issues impacting the industry, and key company profiles.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook